Important data points for CBER non-clinical studies
Reviewer perspective
ABOUT
This webinar is to discuss Center for Biologics Evaluation and Research's (CBER's) support and requirement for the Standard for the Exchange of Nonclinical Data (SEND), which was published in the Federal Register on July 14, 2020, and the addition of SEND for CBER to the FDA Data Standards Catalog. FDA will discuss the background of the new requirement and how SEND will aid CBER reviewers.
AUDIENCE
Regulatory affairs professionals working on non-clinical data submission for Biologics License Applications (BLA) or Investigational New Drug (IND) applications
Foreign regulators
Consultants focused on non-clinical data submission
Drug development professionals specializing in non-clinical data
CONTINUING EDUCATION
Real-time attendance is required for the certificate of attendance. Certificates are only available during the three weeks post-event. This course:
has been pre-approved by RAPS as eligible for up to 1 credits towards a participant's RAC recertification upon full completion.
has been pre-approved by SOCRA who accepts documentation of candidate participation in continuing education programs for re-certification if the program is applicable to clinical research regulations, operations or management, or to the candidate's clinical research therapeutic area.
has been pre-approved by SQA as eligible for 0.25 non-GCP or non-GLP units for every 1 hour of instructional time towards a participant's RQAP re-registration.
has been approved by ACRP for continuing education in clinical research. ACRP will provide 1 ACRP contact hour for every 45-60 minutes of qualified material.
The Small Business and Industry Assistance program in the Center for Drug Evaluation and Research (CDER SBIA) provides guidance, education and regular updates for regulated industry.
This is an automated message delivery system. Replying to this message will not reach the CDER SBIA staff. If you have comments or questions, please contact us at CDERSBIA@fda.hhs.gov or 1-866-405-5367 or (301) 796-6707.
This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration · 10903 New Hampshire Ave · Silver Spring, MD · 20993-0002 · 1-888-INFO-FDA
No comments:
Post a Comment